$Tesla(TSLA.US)Tesla's Optimus Gen3 suddenly received 10,000 orders. PharmAGRI Pharmaceutical Company has signed a letter of intent, one of which is a collaboration with Tesla.
Plans to deploy up to 10,000 Optimus Gen3+ humanoid robots in its SuperPharm and CEA facilities to automate labor and ensure drug transfer control.
These robots have been validated at Tesla's factory, with efficiency 30% higher than manual labor, and costs may drop below $20,000 in the future.
The company's strategic focus is to capture a $10 billion total addressable market (TAM) in federal procurement of plant-based prescription drugs, which are mainly sourced from foreign manufacturers. Although this market is relatively small compared to the entire pharmaceutical industry, it represents a key opportunity to restore control, compliance, and domestic production of plant-based prescription drugs through a fair and transparent pricing model.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
